AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
Arthrex Biotech has raised €1.5M across 1 funding round from 1 investor, most recently a round in Sep 2020. Based in Valencia, Spain; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-09-01 | Other | €1.5M |
| Invivo Capital Partners |
| View deal → |
